• Translational cancer research
• Extracellular vesicles/exosomes
• Cancer diagnostics and therapeutics

The vision of the JC STEM Lab of Personalised Cancer Medicine led by Andreas Möller (Moeller) is to improve cancer patient’s outcome by leveraging innovative findings in the clinical and translational oncology space, combined with extracellular vesicle discoveries, to develop novel solutions for currently unmet clinical needs. This vision is based on unique skill sets in the group, bringing together basic biochemistry, cancer metastasis, immune responses and extracellular vesicle (EV) functions, with the work spanning topics from basic science observations to translation research to clinical solutions. Developing tools and expertise allows us to dissect interactions between cancer cells, innate and adaptive immune cell subsets and their precursors, and the secretome, especially EVs, which promote immune-suppressed, pro-metastatic environments. Based on these findings, the laboratory is ideally placed to determine the regulation, origin and impact of immune cells, particularly myeloid cells, in cancer metastasis, and clinically and commercially develop novel diagnostic and predictive markers, capable of the early identification of cancer and triaging patients into the most appropriate therapy. Furthermore, based on these findings, innovative cancer therapeutics are developed. The work is enabled by strong intellectual property foundations, established multi-disciplinary collaboration networks of oncologists, experts in nanotechnology development, chemists, biophysicists and commercial partners, including experts in clinical point-of-care devices.

Andreas Möller (Moeller) is appointed as Global STEM Professor of Medicine at the Chinese University of Hong Kong (CUHK) and Director of the JC Lab of Precision Cancer Medicine at the Li Ka Shing Institute of Health Sciences, Hong Kong. He is Director of Research in the Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, CUHK. Before joining CUHK in 2023, Andreas was Group Leader of the Tumour Microenvironment Laboratory at the QIMR Berghofer Medical Research Institute, Brisbane, Australia. Andreas received his doctoral training at the German Cancer Research Centre (DKFZ) in Heidelberg, Germany, followed by postdoctoral training at the University of Berne, Switzerland, and the Peter MacCallum Cancer Centre, Melbourne, Australia.

Andreas is an internationally recognized expert and thought leader in the field of translational cancer research, with a focus on the role of extracellular vesicles (EVs; exosomes) and immune cells in cancer progression, and metastasis. His work is highly cited, recognized for its rigour and innovation. He is ranked in the top 0.025% of researchers worldwide in the Extracellular Vesicles topic (SciVal, June 2025), with a field-weighted citation index (FWCI) of 67.3. He published over 100 peer-reviewed articles, with an H index of 55 and 30,000 citations. He serves as President-elect for the International Society of Extracellular Vesicles (ISEV) and is Executive and founding Board Member of the Asian Pacific Societies for Extracellular Vesicles.

Andreas established a large, international network of clinical and scientific collaborations, filed patents in the cancer and EV fields, and with commercial partners is focussing on gaining a better understanding of the role of EVs in cancer progression and their use as cancer biomarkers and therapeutics.

1. Su Y, Visan KS, Voss S, Prieto-Vila M, Matsuzaki J, Chan JYK, Yam JWP, Möller A. Impact of isolation techniques on the content of small extracellular vesicles. Journal of Extracellular Vesicles. 2026;15(6). doi:10.1002/jev2.70290.
2. Lobb RJ, Zhou Q, Fielding D, Visan KS, Wuethrich A, Wang J, Hu Y, Norris EL, Hastie ML, Everitt S, Parris B, Aoude LG, Bonazzi VF, Nixon E, Mooi J, Koo KM, O’Byrne K, Kulasinghe A, Bowman R V, Yang IA, Corcoran NM, Hovens CM, MacManus M, Gorman JJ, Day BW, Hartel G, Whiteman DC, Tebbutt N, Mariadason JM, Fong KM, Barbour AP, Trau M, Möller A. Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. Cell Reports Medicine. 2026;7(4):102694. doi:10.1016/j.xcrm.2026.102694.
3. Ham S, Lima LG, Möller A. The (in)significance of establishing accurate extracellular vesicle nomenclature. Journal of Extracellular Vesicles. 2025;14(11). doi:10.1002/jev2.70203. (Letter)
4. Skvortsova I-I, Berger AC, Huang J, Lee H-H, Wu L-Y, Park S-H, Jakobsson H, Shackleton M, Möller A. Immune regulation and immune therapy in melanoma: Review with emphasis on CD155 signalling. Cancers. 2024;16(11):1950. doi:10.3390/cancers16111950. (Review)
5. Visan KS, Wu LY, Voss S, Wuethrich A, Möller A. Status quo of extracellular vesicle isolation and detection methods for clinical utility. Seminars in Cancer Biology. 2023;88:157-171. doi:10.1016/j.semcancer.2022.12.008. (Review)
6. Lobb RJ, Visan KS, Wu LY, Norris EL, Hastie ML, Everitt S, Yang IA, Bowman R V., Siva S, Larsen JE, Gorman JJ, MacManus M, Leimgruber A, Fong KM, Möller A. An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer. Communications Biology. 2023;6(1):68-. doi:10.1038/s42003-022-04350-4.
7. Visan KS, Lobb RJ, Ham S, Lima LG, Palma C, Edna CPZ, Wu LY, Gowda H, Datta KK, Hartel G, Salomon C, Möller A. Comparative analysis of tangential flow filtration and ultracentrifugation, both combined with subsequent size exclusion chromatography, for the isolation of small extracellular vesicles. Journal of Extracellular Vesicles. 2022;11(9). doi:10.1002/jev2.12266.
8. Visan KS, Lobb RJ, Wen SW, Bedo J, Lima LG, Krumeich S, Palma C, Ferguson K, Green B, Niland C, Cloonan N, Simpson PT, McCart Reed AE, Everitt SJ, Macmanus MP, Hartel G, Salomon C, Lakhani SR, Fielding D, Möller A. Blood-derived extracellular vesicle-associated miR-3182 detects non-small cell lung cancer patients. Cancers. 2022;14(1):257. doi:10.3390/cancers14010257/s1.
9. Lima LG, Ham S, Shin H, Chai EPZ, Lek ESH, Lobb RJ, Müller AF, Mathivanan S, Yeo B, Choi Y, Parker BS, Möller A. Tumor microenvironmental cytokines bound to cancer exosomes determine uptake by cytokine receptor-expressing cells and biodistribution. Nature Communications. 2021;12(1):3543-. doi:10.1038/s41467-021-23946-8.
10. Möller A, Lobb RJ. The evolving translational potential of small extracellular vesicles in cancer. Nature Reviews Cancer. 2020;20(12):697-709. doi:10.1038/s41568-020-00299-w. (Review)
11. Ham S, Lima LG, Lek E, Möller A. The impact of the cancer microenvironment on macrophage phenotypes. Frontiers in Immunology. 2020;11:534832. doi:10.3389/fimmu.2020.01308. (Review)
12. Kekoolani S Visan, Richard J Lobb, Moller A. The role of exosomes in the promotion of epithelial-to-mesenchymal transition and metastasis. Frontiers in Bioscience-Landmark. 2020;25(6):1022-1057. doi:10.2741/4846. (Review)
13. Wiegmans AP, Saunus JM, Ham S, Lobb R, Kutasovic JR, Dalley AJ, Miranda M, Atkinson C, Foliaki ST, Ferguson K, Niland C, Johnstone CN, Lewis V, Collins SJ, Lakhani SR, Al-Ejeh F, Möller A. Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer. JCI Insight. 2019;4(6). doi:10.1172/jci.insight.124092.
14. Wen SW, Lima LG, Lobb RJ, Norris EL, Hastie ML, Krumeich S, Möller A. Breast cancer-derived exosomes reflect the cell-of-origin phenotype. Proteomics. 2019;19(8). doi:10.1002/pmic.201800180.
15. Chen A, Sceneay J, Gödde N, Kinwel T, Ham S, Thompson EW, Humbert PO, Möller A. Intermittent hypoxia induces a metastatic phenotype in breast cancer. Oncogene. 2018;37(31):4214-4225. doi:10.1038/s41388-018-0259-3.
16. Ham S, Lima LG, Chai EPZ, Muller A, Lobb RJ, Krumeich S, Wen SW, Wiegmans AP, Möller A. Breast cancer-derived exosomes alter macrophage polarization via gp130/STAT3 signaling. Frontiers in Immunology. 2018;9(MAY):332444. doi:10.3389/fimmu.2018.00871.
17. Lobb RJ, van Amerongen R, Wiegmans A, Ham S, Larsen JE, Möller A. Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance. International Journal of Cancer. 2017;141(3):614-620. doi:10.1002/ijc.30752.
18. Lobb RJ, Hastie ML, Norris EL, van Amerongen R, Gorman JJ, Möller A. Oncogenic transformation of lung cells results in distinct exosome protein profile similar to the cell of origin. Proteomics. 2017;17(23-24). doi:10.1002/pmic.201600432.
19. Wen SW, Sceneay J, Lima LG, Wong CSF, Becker M, Krumeich S, Lobb RJ, Castillo V, Wong KN, Ellis S, Parker BS, Möller A. The biodistribution and immune suppressive effects of breast cancer-derived exosomes. Cancer Research. 2016;76(23):6816-6827. doi:10.1158/0008-5472.can-16-0868.
20. Lobb RJ, Becker M, Wen SW, Wong CSF, Wiegmans AP, Leimgruber A, Möller A. Optimized exosome isolation protocol for cell culture supernatant and human plasma. Journal of Extracellular Vesicles. 2015;4(1). doi:10.3402/jev.v4.27031.